First-line daraxonrasib (Rasonque) plus gemcitabine and nab-paclitaxel (Abraxane) produced a durable responses and a median progression-free survival (PFS) exceeding 1 year in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC), according to updated data from the phase 1/2 RMC-GI-102 trial (NCT06445062) presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.¹,²
The update adds patients and follow-up to data first presented at the 2026 AACR Annual Meeting, and the combination is now being compared with gemcitabine and nab-paclitaxel alone in the phase 3 RASolute 303 trial (NCT07491445).1,3
Updated findings showed that as of a September 28, 2026, data cutoff, patients in the first-line mPDAC cohort (n = 61) had received daraxonrasib at 200 mg plus gemcitabine and nab-paclitaxel, with a median follow-up of 18.3 months (range, 13.1-23.7).1 The confirmed overall response rate (ORR) was 60.7% (95% CI, 47.3%-72.9%), including complete responses in 8.2% of patients, and the disease control rate (DCR) was 90.2% (95% CI, 79.8%-96.3%). The median duration of response (DOR) was 11.1 months (95% CI, 7.6-18.4), and the median PFS was 12.8 months (95% CI, 10.8-18.4). The estimated 12-month overall survival (OS) rate was 76.6% (95% CI, 63.7%-85.4%).
The safety profile was consistent with the known profiles of daraxonrasib and gemcitabine/nab-paclitaxel, and no new safety signals were identified with longer follow-up.
"With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year," Wungki Park, MD, MS, a medical oncologist at the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center in New York, New York, and an investigator on RMC-GI-102 and RASolute 303, stated in a news release. "The emerging survival signal is meaningful and is estimated at 76.6% for patients to be alive at 1 year. Taken together, these findings provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option."
What was the rationale for evaluating daraxonrasib plus gemcitabine/nab-paclitaxel in first-line mPDAC?
RAS alterations represent the main driver of pancreatic cancer, and daraxonrasib is an oral, RAS(ON) multi-selective, noncovalent, tri-complex inhibitor. In the earlier analysis of RMC-GI-102 presented at the AACR Annual Meeting, patients treated with daraxonrasib plus gemcitabine and nab-paclitaxel (n = 40) achieved an ORR of 58% (95% CI, 41%-73%) and a DCR of 90% (95% CI, 76%-97%) at a median follow-up of 9.7 months (range, 5.7-13.8).³ The estimated 6-month PFS and OS rates were 84% (95% CI, 68%-93%) and 90% (95% CI, 76%-96%), respectively.
Daraxonrasib monotherapy is approved by the FDA for the treatment of adult patients with mPDAC who have received at least 1 prior systemic therapy or who are not candidates for multiagent systemic therapy, and the European Commission approved it for adult patients with mPDAC who have received at least 1 prior systemic therapy.¹ Both approvals were supported by data from the phase 3 RASolute 302 trial (NCT06625320) in previously treated mPDAC.⁴
What was the design of the phase 1/2 RMC-GI-102 trial?
RMC-GI-102 is an open-label, multicenter, nonrandomized phase 1/2 platform study of RAS(ON) inhibitors in patients with gastrointestinal solid tumors; subprotocol C evaluates daraxonrasib plus gemcitabine and nab-paclitaxel in metastatic PDAC.5 Eligible patients were at least 18 years of age and had pathologically or cytologically documented metastatic pancreatic carcinoma; an ECOG performance status of 0 or 1; adequate organ function; and, in the first-line cohort, no prior treatment for metastatic disease and measurable disease per RECIST 1.1 criteria.3,5